Lutetium-177-labeled cG250

Lutetium-177-labeled cG250 · Ludwig Institute for Cancer Research

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Lutetium-177-labeled cG250, covering 2017-03-22 to 2017-03-22. Get the full timeline:

Most recent: Clinical Trial Update: Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer [Phase 1, Phase 2]

See pricing